Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study

Abstract Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome o...

Full description

Saved in:
Bibliographic Details
Main Authors: Dimitrii Pogorelov, Sebastian Felix Nepomuk Bode, Xin He, Javier Ramiro-Garcia, Fanny Hedin, Wim Ammerlaan, Maria Konstantinou, Christophe M. Capelle, Ni Zeng, Aurélie Poli, Olivia Domingues, Guillem Montamat, Oliver Hunewald, Séverine Ciré, Alexandre Baron, Joseph Longworth, Agnieszka Demczuk, Murilo Luiz Bazon, Ingrid Casper, Ludger Klimek, Lorie Neuberger-Castillo, Dominique Revets, Lea Guyonnet, Sylvie Delhalle, Jacques Zimmer, Vladimir Benes, Françoise Codreanu-Morel, Christiane Lehners-Weber, Ilse Weets, Pinar Alper, Dirk Brenner, Jan Gutermuth, Coralie Guerin, Martine Morisset, François Hentges, Reinhard Schneider, Mohamed H. Shamji, Fay Betsou, Paul Wilmes, Enrico Glaab, Antonio Cosma, Jorge Goncalves, Feng Q. Hefeng, Markus Ollert
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-54684-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850064503975182336
author Dimitrii Pogorelov
Sebastian Felix Nepomuk Bode
Xin He
Javier Ramiro-Garcia
Fanny Hedin
Wim Ammerlaan
Maria Konstantinou
Christophe M. Capelle
Ni Zeng
Aurélie Poli
Olivia Domingues
Guillem Montamat
Oliver Hunewald
Séverine Ciré
Alexandre Baron
Joseph Longworth
Agnieszka Demczuk
Murilo Luiz Bazon
Ingrid Casper
Ludger Klimek
Lorie Neuberger-Castillo
Dominique Revets
Lea Guyonnet
Sylvie Delhalle
Jacques Zimmer
Vladimir Benes
Françoise Codreanu-Morel
Christiane Lehners-Weber
Ilse Weets
Pinar Alper
Dirk Brenner
Jan Gutermuth
Coralie Guerin
Martine Morisset
François Hentges
Reinhard Schneider
Mohamed H. Shamji
Fay Betsou
Paul Wilmes
Enrico Glaab
Antonio Cosma
Jorge Goncalves
Feng Q. Hefeng
Markus Ollert
author_facet Dimitrii Pogorelov
Sebastian Felix Nepomuk Bode
Xin He
Javier Ramiro-Garcia
Fanny Hedin
Wim Ammerlaan
Maria Konstantinou
Christophe M. Capelle
Ni Zeng
Aurélie Poli
Olivia Domingues
Guillem Montamat
Oliver Hunewald
Séverine Ciré
Alexandre Baron
Joseph Longworth
Agnieszka Demczuk
Murilo Luiz Bazon
Ingrid Casper
Ludger Klimek
Lorie Neuberger-Castillo
Dominique Revets
Lea Guyonnet
Sylvie Delhalle
Jacques Zimmer
Vladimir Benes
Françoise Codreanu-Morel
Christiane Lehners-Weber
Ilse Weets
Pinar Alper
Dirk Brenner
Jan Gutermuth
Coralie Guerin
Martine Morisset
François Hentges
Reinhard Schneider
Mohamed H. Shamji
Fay Betsou
Paul Wilmes
Enrico Glaab
Antonio Cosma
Jorge Goncalves
Feng Q. Hefeng
Markus Ollert
author_sort Dimitrii Pogorelov
collection DOAJ
description Abstract Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4+ hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8+ counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.
format Article
id doaj-art-4241e882ff6348d9b88a6e9c30ce2b6f
institution DOAJ
issn 2041-1723
language English
publishDate 2024-11-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-4241e882ff6348d9b88a6e9c30ce2b6f2025-08-20T02:49:17ZengNature PortfolioNature Communications2041-17232024-11-0115112210.1038/s41467-024-54684-2Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational studyDimitrii Pogorelov0Sebastian Felix Nepomuk Bode1Xin He2Javier Ramiro-Garcia3Fanny Hedin4Wim Ammerlaan5Maria Konstantinou6Christophe M. Capelle7Ni Zeng8Aurélie Poli9Olivia Domingues10Guillem Montamat11Oliver Hunewald12Séverine Ciré13Alexandre Baron14Joseph Longworth15Agnieszka Demczuk16Murilo Luiz Bazon17Ingrid Casper18Ludger Klimek19Lorie Neuberger-Castillo20Dominique Revets21Lea Guyonnet22Sylvie Delhalle23Jacques Zimmer24Vladimir Benes25Françoise Codreanu-Morel26Christiane Lehners-Weber27Ilse Weets28Pinar Alper29Dirk Brenner30Jan Gutermuth31Coralie Guerin32Martine Morisset33François Hentges34Reinhard Schneider35Mohamed H. Shamji36Fay Betsou37Paul Wilmes38Enrico Glaab39Antonio Cosma40Jorge Goncalves41Feng Q. Hefeng42Markus Ollert43Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Luxembourg Centre for Systems Biomedicine, University of LuxembourgLuxembourg Centre for Systems Biomedicine, University of LuxembourgNational Cytometry Platform, Luxembourg Institute of HealthIntegrated BioBank of Luxembourg, Luxembourg Institute of HealthNational Cytometry Platform, Luxembourg Institute of HealthDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Center for Rhinology and AllergologyCenter for Rhinology and AllergologyIntegrated BioBank of Luxembourg, Luxembourg Institute of HealthNational Cytometry Platform, Luxembourg Institute of HealthDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Genomics Core Facility, European Molecular Biology LaboratoryNational Unit of Immunology-Allergology, Centre Hospitalier de LuxembourgNational Unit of Immunology-Allergology, Centre Hospitalier de LuxembourgDepartment of Clinical Biology/ Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Universitair Ziekenhuis BrusselLuxembourg Centre for Systems Biomedicine, University of LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis BrusselDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH)National Unit of Immunology-Allergology, Centre Hospitalier de LuxembourgNational Unit of Immunology-Allergology, Centre Hospitalier de LuxembourgLuxembourg Centre for Systems Biomedicine, University of LuxembourgImmunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College LondonIntegrated BioBank of Luxembourg, Luxembourg Institute of HealthDepartment of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of LuxembourgLuxembourg Centre for Systems Biomedicine, University of LuxembourgNational Cytometry Platform, Luxembourg Institute of HealthLuxembourg Centre for Systems Biomedicine, University of LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH)Department of Infection and Immunity, Luxembourg Institute of Health (LIH)Abstract Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4+ hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8+ counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.https://doi.org/10.1038/s41467-024-54684-2
spellingShingle Dimitrii Pogorelov
Sebastian Felix Nepomuk Bode
Xin He
Javier Ramiro-Garcia
Fanny Hedin
Wim Ammerlaan
Maria Konstantinou
Christophe M. Capelle
Ni Zeng
Aurélie Poli
Olivia Domingues
Guillem Montamat
Oliver Hunewald
Séverine Ciré
Alexandre Baron
Joseph Longworth
Agnieszka Demczuk
Murilo Luiz Bazon
Ingrid Casper
Ludger Klimek
Lorie Neuberger-Castillo
Dominique Revets
Lea Guyonnet
Sylvie Delhalle
Jacques Zimmer
Vladimir Benes
Françoise Codreanu-Morel
Christiane Lehners-Weber
Ilse Weets
Pinar Alper
Dirk Brenner
Jan Gutermuth
Coralie Guerin
Martine Morisset
François Hentges
Reinhard Schneider
Mohamed H. Shamji
Fay Betsou
Paul Wilmes
Enrico Glaab
Antonio Cosma
Jorge Goncalves
Feng Q. Hefeng
Markus Ollert
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
Nature Communications
title Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
title_full Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
title_fullStr Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
title_full_unstemmed Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
title_short Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
title_sort multiomics approaches disclose very early molecular and cellular switches during insect venom allergen specific immunotherapy an observational study
url https://doi.org/10.1038/s41467-024-54684-2
work_keys_str_mv AT dimitriipogorelov multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT sebastianfelixnepomukbode multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT xinhe multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT javierramirogarcia multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT fannyhedin multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT wimammerlaan multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT mariakonstantinou multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT christophemcapelle multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT nizeng multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT aureliepoli multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT oliviadomingues multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT guillemmontamat multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT oliverhunewald multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT severinecire multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT alexandrebaron multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT josephlongworth multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT agnieszkademczuk multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT muriloluizbazon multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT ingridcasper multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT ludgerklimek multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT lorieneubergercastillo multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT dominiquerevets multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT leaguyonnet multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT sylviedelhalle multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT jacqueszimmer multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT vladimirbenes multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT francoisecodreanumorel multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT christianelehnersweber multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT ilseweets multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT pinaralper multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT dirkbrenner multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT jangutermuth multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT coralieguerin multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT martinemorisset multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT francoishentges multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT reinhardschneider multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT mohamedhshamji multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT faybetsou multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT paulwilmes multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT enricoglaab multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT antoniocosma multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT jorgegoncalves multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT fengqhefeng multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy
AT markusollert multiomicsapproachesdiscloseveryearlymolecularandcellularswitchesduringinsectvenomallergenspecificimmunotherapyanobservationalstudy